Dysbiosis Enhancing Linkage Towards Association with Canine Hemangiosarcoma (DEL-HSA)
OpenDescription
Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival.
The Intestinal Dysbiosis Program is investigating the associations between the presence of dysbiosis and the development and metastasis of HSA.
Eligibility Criteria
- Dogs being concurrently enrolled in the Ethos-PUSH trial.
Participation in a clinical study is subject to medical eligibility and availability requirements. Financial incentives, including potential stipends or reimbursements, are contingent upon meeting study criteria and completing required visits or activities. Additional terms and conditions may apply.